勵晶太平洋(00575.HK)2024年度股東應占虧損較去年大幅減少
格隆匯3月27日丨勵晶太平洋(00575.HK)公佈年度業績,公司股東應占虧損較去年大幅減少,約為448萬美元,主要是由於集團的營運及研發開支約499萬美元。
2024年是公司再一次取得戰略性進展的一年,標誌着公司於戰略之旅中達成若干重要里程碑。公司的商業戰略合作夥伴江蘇萬邦醫藥於年底向中國國家藥品監督管理局提交新藥申請。此外,江蘇萬邦醫藥已於2025年3月24日收到國家藥品監督管理局之確認,先前提交之新藥申請註冊檔案已通過國家藥品監督管理局評審程序第一階段,該檔案已滿足所有監管規定。國家藥品監督管理局現將繼續進行下一階段的評審程序,其將對新藥申請所提交的數據進行技術評估。倘國家藥品監督管理局並無發現任何缺陷,江蘇萬邦醫藥預計自提交日期起12個月內獲得營銷許可。獲得批准後,集團預計將於中國的商業化中獲得500萬美元(預扣税前)及額外200萬美元(預扣税前)。
公司亦已將Fortacin™的權利「對外授權」予日本市場的Kobayashi Pharmaceutical Co., Ltd.,並與公司的合同研究機構(CRO)敲定美國市場的第三期臨牀研究預算。公司於Deep Longevity的研發,成功開發出新的大型語言模型(「LLM」),廣受客户歡迎。公司現正尋求於本年度及未來引入新客户。公司對Senstend™的未來潛力仍然充滿信心,該藥物可能在上市第一年就能幫助中國約900萬名患者的初始目標市場,並在第十年增加到逾1.7億名患者。公司有強大的合作夥伴江蘇萬邦醫藥,作為復星網絡的一部分,江蘇萬邦醫藥擁有專業的市場營銷知識、成熟的電子商務平台以及無與倫比的全國醫院、診所及藥店分銷網絡,有助於確保Senstend™在中國取得商業成功。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.